Search

Researchers from the National Autonomous University of Mexico (UNAM) conducted a systematic review and meta-analysis on the relationship between TP53 oncogenic variants and prognosis in patients with glioblastoma. The study included 23 papers with 2,555 patients, finding that TP53 variants were associated with a reduced likelihood of 1-year survival. However, the analysis did not show a significant impact of TP53 variants on overall survival, progression-free survival, or 2-year survival. The researchers concluded that genetic variants in TP53 do not provide useful prognostic information for glioblastoma. [Extracted from the article]

A research paper published in Oncoscience discusses the potential of the cancer testis antigen DDX53 as an early esophageal cancer antigen. The study explores the role of T-lymphocytes in creating a pro-inflammatory microenvironment that worsens prognosis for esophageal carcinoma. The researchers identified tumor resident T-cell receptor complementarity determining region-3 (CDR3) amino acid sequences and evaluated their chemical complementarity with CTAs. The study found that high TCR CDR3-DDX53 complementarity correlated with worse disease-free survival and a greater proportion of tumor samples lacking DDX53 expression. These findings suggest that the TCR-antigen interaction may induce selective pressure resulting in antigen loss and tumor cell escape from the immune response. [Extracted from the article]

A secondary analysis of data from the S1314 clinical trial, conducted by the SWOG Cancer Research Network, examined the association of molecular subtypes in muscle-invasive bladder cancer (MIBC) with response to neoadjuvant chemotherapy, progression, and survival. The study found that considering the molecular subtype of MIBC based on tumor RNA expression can enhance the predictive ability of the COXEN score, a tumor biomarker, for chemotherapy response. However, individual molecular subtypes did not significantly impact overall survival or progression-free survival. The authors suggest that prospective clinical trials are needed to further investigate the association between molecular subtypes and patient outcomes. [Extracted from the article]

Keywords: Biomarkers; Cancer; Carcinomas; Diagnostics and Screening; Health and Medicine; Hemic and Immune Systems; Immunology; Lymph Nodes; Lymphoid Tissue; Oncology; Prognostic Markers EN Biomarkers Cancer Carcinomas Diagnostics and Screening Health and Medicine Hemic and Immune Systems Immunology Lymph Nodes Lymphoid Tissue Oncology Prognostic Markers 1337 1337 1 06/19/23 20230620 NES 230620 2023 JUN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Oncology Week -- Research findings on carcinomas are discussed in a new report. According to the news reporters, the research concluded: "Positive lymph node status significantly worsens prognosis in patients with microinvasive breast carcinoma.". [Extracted from the article]

This document provides information about an ongoing clinical trial in China that is investigating the use of immunotherapy combined with microwave ablation (MWA) for the treatment of advanced hepatocellular carcinoma (HCC), a type of liver cancer. Immunotherapy is currently recommended as the main treatment for HCC, and MWA treatment may enhance its effectiveness by stimulating a peripheral immune response. The trial aims to evaluate the need for combining immunotherapy with targeted drugs or MWA in real-world clinical practice and hopes to provide valuable clinical data for the treatment selection of HCC patients. The trial is expected to be completed by January 2025 and is not currently recruiting new participants. [Extracted from the article]

A recent report from Heilongjiang University of Chinese Medicine in China provides updated information on the relationship between the peritoneal cancer index (PCI) and the postoperative prognosis of patients with advanced ovarian cancer. The study used meta-analysis to assess the prognostic value of PCI in these patients and found that those with a high PCI had a worse prognosis compared to those with a low PCI. The study suggests that PCI may be used as an indicator of postoperative prognosis in patients with advanced ovarian cancer, but further research is needed to confirm these findings. [Extracted from the article]

The article focuses on the impact of metastasis-directed radiation therapy (MDT) on progression-free survival in metastatic pancreatic cancer. Topics include the comparison of MDT plus chemotherapy to standard chemotherapy, the correlation between MDT and increased immune responses, and the exploration of MDT's effectiveness through the EXTEND Phase II trial.

The article discusses the use of composite endpoints to boost the statistical sensitivity of clinical trials without ballooning costs. According to Joshua Stolker, a cardiologist at Mercy Clinic in Saint Louis, Missouri, people should choose endpoints that are similar in how clinically important they are to patients. Radiation oncologist Loren Mell also considers the event-free survival as a composite endpoint because it includes death from multiple different causes.

A new study conducted by researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective in treating locally advanced pancreatic cancer. The study, led by the late Cullen Taniguchi, M.D., Ph.D., and published in The Lancet Oncology, showed that the combination of a drug called avasopasem manganese with radiation therapy resulted in higher progression-free survival and overall response rates compared to a placebo. The trial involved some of the highest doses of radiation ever given to pancreatic cancer patients, and the results have led to an expanded Phase II trial. [Extracted from the article]

The article focuses on a study conducted by Boris Gershman and colleagues at Mayo Clinic in Rochester, Minnesota which discusses the correlation of blood type A to the increased risk of bladder cancer mortality for patients who undergo radical cystectomy (RC). Topics include the survival rate for O blood type patients, potential role for ABO blood type in tumor immunology, and association between blood type and disease recurrence.

Roche's ipatasertib has improved progression-free survival in a subgroup of prostate cancer patients in a phase 3 trial. The drug failed to improve outcomes in the broader population, but, with overall survival data still maturing, Roche thinks the findings are encouraging for its chances of claiming a slice of a market targeted by AstraZeneca. [ABSTRACT FROM AUTHOR]

The article reports on the generation of anaplastic lymphoma kinase (ALK) inhibitor Brigatinib (Alunbrig) which prolonged the median progression-free survival (PFS) in patient with advanced ALK-positive non-small-cell lung cancer. Topics mention including the ALTA-1L clinical trial, intracranial response and drug adverse events.

The article presents a study which showed that neutropenia and hypertension that develop while on sunitinib therapy for metastatic renal cell carcinoma (mRCC) are independently linked with better survival. The study was conducted by Doctor Frede Donskov of Aarhus University Hospital in Denmark and colleagues and is published at the "British Journal of Cancer." The study also showed that ontreatment neutropenia and hypertension were linked with longer progression-free survival (PFS).

The article reports on a study which claimed that an initial degarelix are effective in improving the prostate-specific antigen (PSA) progression-free survival of patients with prostate cancer (PCa).